Back
Deals and Wins

Foley Represents TCGX in $30M Private Placement Financing in Nektar Therapeutics

12 April 2024

Foley & Lardner LLP represented TCG Crossover (“TCGX”) in the $30 million private placement financing in Nektar Therapeutics, a biotechnology company developing medicines for the treatment of auto-immune disorders.

Nektar Therapeutics is a biotechnology company with a wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. This financing will further bolster the company’s financial position and extend its cash runway well into the third quarter of 2026.

TCGX supports private and public companies building the future of medicine. As a Palo Alto-based investment firm focused on investing in innovative pre-IPO and public drug discovery companies, TCGX invests in visionary entrepreneurs leveraging recent scientific breakthroughs to develop transformative medicines.

The Foley team was led by partners Louis Lehot and Clyde Tinnen with support from associate Trevor Mullin.

People

Louis Lehot

Partner

Silicon Valley 650.251.1222

Clyde Tinnen

Partner

Milwaukee 414.297.5026

Trevor A. Mullin

Associate

Los Angeles 213.972.4618

Related News

View All Posts
29 April 2024 Deals and Wins

Foley Advises UF Health Jacksonville in Joint Venture with Select Medical

Foley & Lardner LLP represented UF Health Jacksonville in its formation of a joint venture with Select Medical to provide inpatient rehabilitative care to northern Florida.
22 April 2024 Deals and Wins

Foley Advises Quanex in Agreement to Acquire Tyman

Foley & Lardner LLP is serving as legal advisor to Quanex Building Products Corporation in its agreement to acquire Tyman in a recommended cash and share offer at an enterprise value of approximately $1.1 billion.
22 April 2024 Deals and Wins

Foley Represents AI Pioneer Matterport in Definitive Agreement to be Acquired by CoStar Group

Foley & Lardner LLP is representing Matterport, Inc. in its proposed acquisition by CoStar Group for an estimated equity value of approximately $2.1 billion and an enterprise value of approximately $1.6 billion.